Discovering and developing novel therapeutics targeting GPCR heteromers in cancer
Every Hope Matters
HyeonGyu Seo, a senior researcher at GPCR Therapeutics, Inc., has been selected to participate in the Single-cell RNA-seq & network analysis using Galaxy and Cytoscape course, provided by European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI) on April 26-30, 2021. Only 30 scientists from around the world are admitted to this hands-on, interactive bioinformatics program. GPCR Therapeutics, Inc. is committed to exploit complex biological information in its Translational Medicine efforts to select the right patient for the right treatment as the company moves forward.
유럽 생물정보학 연구소(EMBL-EBI)가 주최하는 Single-cell RNA-seq & network analysis using Galaxy and Cytoscape 프로그램에 ㈜지피씨알의 서현규 박사가 참가하게 되었습니다. 2021년 4월 26일부터 30일까지 총 5일 간 진행되는 이 교육 프로그램에서는 최신 생물정보학 활용법이 다뤄지며, 전 세계에서 최종 선정된 30명만이 참여 기회를 얻게 됩니다. 이로써 ㈜지피씨알은 강화된 내부 중개의학 연구 역량을 기반으로 빅데이터를 활용하여 보다 나은 환자 맞춤형 치료를 위해 앞으로 나아갈 수 있게 되었습니다.
The incorporation of GPCR Therapeutics USA, INC.
We are proud to announce that the Secretary of State of the State of California certified the incorporation of GPCR Therapeutics USA, INC. on April 7, 2021. GPCR Therapeutics is currently searching for laboratory space in the San Francisco Bay area and has plans to expand and grow our U.S. site. The focus of the site will be both Research and Development in Oncology. The most advanced clinical candidate is Burixafor, which is planned to initiate a clinical trial in the US next year, to prove our CXCR4 heteromer hypothesis. Additionally, we will be utilizing our technologies to identify key GPCR heteromers as therapeutics targets in Oncology. Dr. Pina Cardarelli will be heading up the team of talented researchers that will be expanding in the coming years.
